Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-9.
Slevin ML, Papamichael D, Rougier P, Schmoll HJ. Current controversies in cancer: Is there a standard adjuvant treatment for colon cancer? Eur J Cancer 1998; 34: 1652-63.
Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-42.
Bours V, Jerusalem G, Fillet G. Le cancer colorectal: prévention et traitement adjuvant. Rev Med Liège 1998; 53: 167-70.
Jerusalem G, Bours V, Fillet G. Traitement du cancer colorectal: aspects pharmaco-économiques. Rev Med Liège 1998; 53: 276-8.
Riethmüller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788-94.
Willett CG, Haller D, Steele G. Controversies in the management of localized rectal cancer. ASCO Educational Book. Spring, 1999; 212-21.
Al Bowen Benson III. Therapy for advanced colorectal cancer. Seminars in Oncology 1998; 25 (Suppl. 11): 2-11.
Jerusalem G, Bours V, Fillet G. Approche thérapeutique du cancer colorectal métastatique. Rev Med Liège 1998; 53: 318-21.
Hustinx R, Paulus P, Jacquet N, Jerusalem G, Bury T, Rigo P. Clinical evaluation of whole-tody 18F-fluorodeoxyglucose positron emission tomography in the detection of liver meta stases. Ann Oncol 1998; 9: 397-401.
Maughan TS, James RD, Kerr D, et al. Preliminary results of a multicenter randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18 (abstract 1007): 262a.
Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352; 1413-8.
Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
Saltz LB, Locker PK, Pirotta N, Elfring GL, Miller LL. Weekly irinotecan (CPT11), leucovorin (LV) and fluorouracil (FU) is superior to daily × 5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1999; 18 (abstrac t898): 233a.
Douillard JY, Cunningham D, Roth AD, et al. A randomized phase III trial comparing irinotecan (IRI) + 5Fu/folinic acid (FA) to the same schedule of 5Fu-FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT). Proc Am Soc Clin Oncol 1999; 18 (abstract 899): 233a.
Pazdur R. New agents for colorectal cancers: Oral fluorinated pyrimidines and oxaliplatin. ASCO Educational Book. Spring, 1998; 300-10.
Levi F, Zidani R, Misset JL. Randomised multicenter trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6.
Cox JV, Pazdur R, Thibault A, et al. A phase III trial of Xeloda® (capecitabine) in previously untreated advanced metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18 (abstract 1016): 265a.
Punt CJA, Keizer HJ, Douma J, et al. Multicenter randomized trial of 5-fluorouracil (5Fu) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in patients (pts) with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1999; 18 (abstract 1006): 262a.